Clinical lung cancer最新文献

{"title":"Completion of Pembrolizumab in Advanced Non-Small Cell Lung Cancer—Real World Outcomes After Two Years of Therapy (COPILOT)","authors":"Andrew Fantoni ,&nbsp;Lydia Warburton ,&nbsp;Benjamin Solomon ,&nbsp;Marliese Alexander ,&nbsp;Meghana Maddula ,&nbsp;Lauren Julia Brown ,&nbsp;Ines Pires da Silva ,&nbsp;Adnan Nagrial ,&nbsp;Farah Abu Al-Hial ,&nbsp;Malinda Itchins ,&nbsp;Nick Pavlakis ,&nbsp;Samantha Bowyer","doi":"10.1016/j.cllc.2024.04.008","DOIUrl":"10.1016/j.cllc.2024.04.008","url":null,"abstract":"<div><h3>Background</h3><p>Seminal trials with first-line pembrolizumab for metastatic non-small cell lung cancer (NSCLC) mandated a maximum two-years treatment. We describe real-world outcomes of a multi-site Australian cohort of patients who completed two-years of pembrolizumab.</p></div><div><h3>Methods</h3><p>Retrospective data were collected from the national AUstralian Registry and biObank of thoRacic cAncers (AURORA). Primary endpoints were progression rate post pembrolizumab discontinuation; and progression free survival (PFS). Local treatment of oligoprogressive disease during pembrolizumab was allowed.</p></div><div><h3>Results</h3><p>A total of 71 patients from six centers, median age 66.0 years, 49% male and 90% ECOG ≤ 1 were identified. Patients were Caucasian (82%) or Asian (16%); past (66%) or current (24%) smokers with mean 37 pack-years. Histology comprised 73% adenocarcinoma and 16% squamous. 18 patients (25%) had brain metastases at diagnosis. Median PD-L1 tumor proportion score (TPS) was 68%; 12 patients (17%) TPS &lt; 1% and 43 (61%) TPS ≥ 50%. No patients had <em>EGFR/ALK/ROS1</em> alterations; 29/49 tested (60%) had <em>KRAS</em> mutations.</p><p>Median follow up was 38.7 months. Objective response rate 78.6%. Median PFS 46.1 months (95% CI 39.5-NR), not reached (46.1-NR) in PD-L1 TPS ≥ 1% versus 28.1 months (16.3-NR) in TPS &lt; 1% (<em>P</em> = .013). 17 patients (24%) received additional local therapy for oligoprogression. Post pembrolizumab discontinuation, 20 patients (28%) had disease progression. Higher rates of progression occurred with TPS &lt; 1% (OR 3.46, <em>P</em> = .06), without complete response (OR 5.06, <em>P</em> = .04), and with treated oligoprogression (OR 3.11, <em>P</em> = .05). 36-month landmark survival was 98.2%.</p></div><div><h3>Conclusion</h3><p>Patients completing two-years of pembrolizumab for NSCLC in an Australian cohort had high rates of <em>KRAS</em> mutation and PD-L1 expression; a proportion had brain metastases and treated oligoprogression. Progression post pembrolizumab was higher in PD-L1 TPS &lt; 1% and in those without complete response.</p></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1525730424000512/pdfft?md5=524d5c384a3ad5567016e7b9d7b96cf3&pid=1-s2.0-S1525730424000512-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140785750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The EXcellenT trial: Exercise in Extended oncogene addicted Lung Cancer in Active Treatment","authors":"Chiara Bennati, Roberto Ferrara, Sabina Sangaletti, Stefano Tamberi, Andrea Spadoni, Giuseppe Attisani, Silvano Zanuso, Jenny Longobardi, Annalisa Morigi, Michela Spreafico, C. Zingaretti, Francesca Fabbri, Elena Carlotti, Elisabetta Fabbri, Livia Turci, M. D'Arcangelo","doi":"10.1016/j.cllc.2024.07.008","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.07.008","url":null,"abstract":"","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141689399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Small Cell Lung Cancer in Norway: Patterns of Care by Health Region and Survival Trends","authors":"Yngvar Nilssen ,&nbsp;Odd Terje Brustugun ,&nbsp;Lars Fjellbirkeland ,&nbsp;Bjørn Henning Grønberg ,&nbsp;Per Magnus Haram ,&nbsp;Nina Helbekkmo ,&nbsp;Åslaug Helland ,&nbsp;Sissel Gyrid Freim Wahl ,&nbsp;Marianne Aanerud ,&nbsp;Steinar Solberg","doi":"10.1016/j.cllc.2024.04.002","DOIUrl":"10.1016/j.cllc.2024.04.002","url":null,"abstract":"<div><h3>Introduction/Background</h3><p>There has been a marked survival improvement for patients with non–small-cell lung cancer. We describe the national trends in characteristics and survival, and geographical differences in diagnostic workup, treatment, and survival for patients with small-cell lung cancer (SCLC).</p></div><div><h3>Materials and Methods</h3><p>Patients registered with SCLC at the Cancer Registry of Norway in 2002 to 2022 were included. Trends in overall survival were estimated for all SCLC patients, patients with limited stage SCLC, patients undergoing surgery, and by health region. Adjusting for case-mix, a multivariable Cox regression was performed examining the association between health region and death.</p></div><div><h3>Results</h3><p>The study included 8374 patients. The stage distribution remained unchanged during the study period. The 5-year overall survival increased from 7.7% to 22.8% for patients with limited stage. The use of multidisciplinary team meetings varied from 62.5% to 85.7%, and the use of positron emission tomography-computer tomography varied from 70.4% to 86.2% between the health regions. Treatment patterns differed markedly between the health regions, with the proportion dying without any registered treatment ranging from 1.2% to 10.9%. For limited stage patients in 2018 to 2022, the median overall survival ranged from 16.5 to 25.5 months across health regions, and the 5-year overall survival ranged from 18.7% to 28.7% (<em>P</em> = .019).</p></div><div><h3>Conclusion</h3><p>The survival for patients with SCLC remains poor. The use of diagnostic procedures, treatment modalities, and survival differed between regions, warranting investigations to further explore the reasons.</p></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1525730424000469/pdfft?md5=4ee53d36e5d86b95a9831a336a40e19c&pid=1-s2.0-S1525730424000469-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140773956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Efficacy and Safety of Durvalumab Administration Following Chemoradiotherapy in Elderly Patients with Unresectable Locally Advanced Non-Small Cell Lung Cancer: A Multicenter, Retrospective Study","authors":"Yosuke Kakiuchi, K. Saruwatari, K. Murotani, T. Tokito, Toyohisa Iriki, Jun Iwakawa, Y. Sakata, Naoki Shingu, S. Saeki, M. Inaba, Akira Takaki, Shunsuke Misono, T. Suetsugu, Koichi Azuma, Keiko Mizuno, T. Sakagami","doi":"10.1016/j.cllc.2024.07.001","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.07.001","url":null,"abstract":"","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141688468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of Venous Thromboembolism in Patients With Stage III and IV Non–Small-Cell Lung Cancer: Nationwide Descriptive Cohort Study","authors":"Anne Gulbech Ording ,&nbsp;Thomas Decker Christensen ,&nbsp;Flemming Skjøth ,&nbsp;Simon Noble ,&nbsp;Anette Arbjerg Højen ,&nbsp;Amalie Lambert Mørkved ,&nbsp;Torben Bjerregaard Larsen ,&nbsp;Rene Horsleben Petersen ,&nbsp;Peter Meldgaard ,&nbsp;Erik Jakobsen ,&nbsp;Mette Søgaard","doi":"10.1016/j.cllc.2024.04.004","DOIUrl":"10.1016/j.cllc.2024.04.004","url":null,"abstract":"<div><h3>Background</h3><p>Venous thromboembolism (VTE) is a common complication in patients starting cancer therapies for non–small-cell lung cancer (NSCLC). We examined the risk and timing of VTE in patients with stage IIIA, IIIB to C, and stage IV NSCLC according to received cancer treatments.</p></div><div><h3>Materials and Methods</h3><p>A nationwide registry-based cohort study of patients recorded in the Danish Lung Cancer Registry (2010-2021) followed for 1 year after entry into the registry to assess the incidence of VTE. The Aalen–Johansen estimator was used to calculate the risk of VTE after treatment commencement with chemotherapy, radiotherapy, chemoradiation, immunotherapy, and targeted therapy.</p></div><div><h3>Results</h3><p>Among the 3475 patients with stage IIIA, 4047 with stage IIIB to C, and 18,082 patients with stage IV cancer, the 1-year risk of VTE was highest in the first 6 months and varied markedly by cancer stage and cancer treatment. In stage IIIA, VTE risk was highest with chemotherapy (3.9%) and chemoradiation (4.1%). In stage IIIB to C, risks increased with chemotherapy (5.2%), immunotherapy (9.4%), and targeted therapy (6.0%). Stage IV NSCLC showed high risk with targeted therapy (12.5%) and immunotherapy (12.2%). The risk was consistently higher for pulmonary embolism than deep vein thrombosis.</p></div><div><h3>Conclusion</h3><p>VTE risks vary substantially according to cancer treatments and cancer stages. The highest risk was observed in the initial 6 months of therapy initiation. These insights emphasize the need for tailored risk assessment and vigilance in managing VTE complications in patients with NSCLC. Further research is needed to optimize individual thromboprophylaxis strategies for patients with unresectable and metastatic NSCLC.</p></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1525730424000470/pdfft?md5=49daabe52b189d14e59cff5d3bb3859a&pid=1-s2.0-S1525730424000470-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140810275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prehabilitation for Older Adults Undergoing Lung Cancer Surgery: A Literature Review and Needs Assessment","authors":"Jane Y. Zhao, Carolyn Presley, M. L. Madariaga, Mark Ferguson, Robert E. Merritt, P. Kneuertz","doi":"10.1016/j.cllc.2024.07.004","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.07.004","url":null,"abstract":"","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141699511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Durvalumab on the Duration and Complexity of Corticosteroid Therapy for Pneumonitis after Chemoradiotherapy","authors":"Saori Murata, H. Horinouchi, Momoko Morishita, S. Kaku, Y. Shinno, Y. Okuma, T. Yoshida, Y. Goto, N. Yamamoto, T. Kashihara, K. Okuma, Masahiko Kusumoto, Y. Ohe","doi":"10.1016/j.cllc.2024.06.009","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.06.009","url":null,"abstract":"","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141704697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Barriers to Completing Low Dose Computed Tomography Scan for Lung Cancer Screening","authors":"Lye-Yeng Wong ,&nbsp;Sania Choudhary ,&nbsp;Ntemena Kapula ,&nbsp;Margaret Lin ,&nbsp;Irmina A. Elliott ,&nbsp;Brandon A. Guenthart ,&nbsp;Douglas Z. Liou ,&nbsp;Leah M. Backhus ,&nbsp;Mark F. Berry ,&nbsp;Joseph B. Shrager ,&nbsp;Natalie S. Lui","doi":"10.1016/j.cllc.2024.04.014","DOIUrl":"10.1016/j.cllc.2024.04.014","url":null,"abstract":"<div><h3>Introduction</h3><p>Annual low-dose computed tomography (LDCT) screening has been shown to reduce lung cancer mortality in high-risk individuals by detecting the disease at an earlier stage. This study aims to assess the barriers to completing LDCT in a cohort of patients who were determined eligible for lung cancer screening (LCS).</p></div><div><h3>Methods</h3><p>We performed a single institution, mixed methods, cross-sectional study of patients who had a LDCT ordered from July to December 2022. We then completed phone surveys with patients who did not complete LDCT to assess knowledge, attitude, and perceptions toward LCS.</p></div><div><h3>Results</h3><p>We identified 380 patients who met inclusion criteria, including 331 (87%) who completed LDCT and 49 (13%) who did not. Patients who completed a LDCT and those who did not were similar regarding age, sex, race, primary language, household income, body mass index, median pack years, and quit time. Positive predictors of LDCT completion were: meeting USPSTF guidelines (97.9% vs 81.6%), being married (58.3% vs 44.9%), former versus current smokers (55% vs 41.7%), personal history of emphysema (60.4% vs 42.9%), and family history of lung cancer (13.9% vs 4.1%) (all <em>P</em> &lt; .05). Of the patients who participated in the phone survey, only 7% of respondents thought they were high risk for developing lung cancer despite attending a shared decision-making visit and only 10% wanted to re-schedule their LDCT.</p></div><div><h3>Conclusion</h3><p>There exist barriers to completing LDCT even after patients are identified as eligible and complete a shared decision-making visit secondary to knowledge barriers, misperceptions, and patient disinterest.</p></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1525730424000706/pdfft?md5=9857917bc79dd90e0582b4b357ae06cf&pid=1-s2.0-S1525730424000706-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140928508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine Learning-Based Prediction of Pathological Responses and Prognosis After Neoadjuvant Chemotherapy for Non–Small-Cell Lung Cancer: A Retrospective Study","authors":"Zhaojuan Jiang ,&nbsp;Qingwan Li ,&nbsp;Jinqiu Ruan ,&nbsp;Yanli Li ,&nbsp;Dafu Zhang ,&nbsp;Yongzhou Xu ,&nbsp;Yuting Liao ,&nbsp;Xin Zhang ,&nbsp;Depei Gao ,&nbsp;Zhenhui Li","doi":"10.1016/j.cllc.2024.04.006","DOIUrl":"10.1016/j.cllc.2024.04.006","url":null,"abstract":"<div><h3>Background</h3><p>Neoadjuvant chemotherapy has variable efficacy in patients with non–small-cell lung cancer (NSCLC), yet reliable noninvasive predictive markers are lacking. This study aimed to develop a radiomics model predicting pathological complete response and postneoadjuvant chemotherapy survival in NSCLC.</p></div><div><h3>Materials and Methods</h3><p>Retrospective data collection involved 130 patients with NSCLC who underwent neoadjuvant chemotherapy and surgery. Patients were randomly divided into training and independent testing sets. Nine radiomics features from prechemotherapy computed tomography (CT) images were extracted from intratumoral and peritumoral regions. An auto-encoder model was constructed, and its performance was evaluated. X-tile software classified patients into high and low-risk groups based on their predicted probabilities. survival of patients in different risk groups and the role of postoperative adjuvant chemotherapy were examined.</p></div><div><h3>Results</h3><p>The model demonstrated area under the receiver operating characteristic (ROC) curve of 0.874 (training set) and 0.876 (testing set). The larger the area under curve (AUC), the better the model performance. Calibration curve and decision curve analysis indicated excellent model calibration (Hosmer–Lemeshow test, <em>P</em> = .763, the higher the <em>P</em>-value, the better the model fit) and potential clinical applicability. Survival analysis revealed significant differences in overall survival (<em>P</em> = .011) and disease-free survival (<em>P</em> = .017) between different risk groups. Adjuvant chemotherapy significantly improved survival in the low-risk group (<em>P</em> = .041) but not high-risk group (<em>P</em> = 0.56).</p></div><div><h3>Conclusion</h3><p>This study represents the first successful prediction of pathological complete response achievement after neoadjuvant chemotherapy for NSCLC, as well as the patients’ survival, utilizing intratumoral and peritumoral radiomics features.</p></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140841631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Safety and Clinical Activity of Front-line Treatment with Cadonilimab plus Chemotherapy in Advanced/Metastatic Non-small Cell Lung Cancer Harboring STK11 Genetic Aberration: A Protocol of Phase II Study","authors":"Huixin Jiang, Ningning Sun, Ru Li, Wenhui Guan, Yue Zhu, Z. Xie, Xiaohong Xie, Ming Liu, Xinqing Lin, Chengzhi Zhou","doi":"10.1016/j.cllc.2024.07.006","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.07.006","url":null,"abstract":"","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141696015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}